BioNTech SE (BNTX) — Quality & forensics
As of 2026-11-17 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 54
- Quality 23
- Growth 5
- Balance sheet 57
- Cash quality 70
- Capital allocation 20
- Momentum 36
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the BNTX chart & overview · the earnings record
FAQ · from the current data · as of 2026-11-17
Quick answers
What is BioNTech SE's Closelooknet quality reading?
The composite reads 35/100 across 7 modules, as of 2026-11-17: valuation 54, quality 23, growth 5, balance sheet 57, cash quality 70, capital allocation 20, momentum 36. Closelooknet scores are research diary readings, not ratings or investment advice.
What is BioNTech SE's Altman Z-Score?
6.65, which sits in the safe zone (above 2.99) as of 2026-11-17. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is BioNTech SE's Piotroski F-Score?
5 of 9, as of 2026-11-17. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does BioNTech SE's Beneish M-Score indicate?
-3.09 — below the −1.78 manipulation-risk threshold, as of 2026-11-17. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- ASML.AS ASML Holding N.V.
- SAN.PA Sanofi SA
- TEMN.SW Temenos Group AG
- WKL.AS Wolters Kluwer N.V.
- CEVI.ST CellaVision AB
- REL.L Relx PLC
- PATH Uipath Inc
- SECT-B.ST Sectra AB (publ)
- DSY.PA Dassault Systemes SE
- HEXA-B.ST Hexagon AB (publ)
- OXIG.L Oxford Instruments PLC
- NEM.DE Nemetschek AG O.N.
- HALO Halozyme Therapeutics Incindustry
- ONC BeOne Medicines AGindustry
- REGN Regeneron Pharmaceuticals Incindustry
- ARGX.BR Argen-Xindustry
- RIGL Rigel Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- SLS Sellas Life Sciences Group Incindustry
- REPL Replimune Group Incindustry